End the abstract-to-paper gap: require full results with any conference presentation
Trial results are often presented at conferences months or years before the full paper appears, leaving doctors to act on slides. Require that the full structured results are published the same day.
Practice-changing results are frequently presented as late-breaking abstracts with full publication lagging a year or more, and some never appear. The proposal is a joint policy of the major congresses and journals: any presented phase 3 result must be accompanied by simultaneous publication or deposition of the full structured results package (protocol, statistical analysis plan, results tables), with the abstract itself openly licensed.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
- Failures are hidden · Negative trials, failed drugs and abandoned programmes are rarely published, so the same mistakes are repeated.
Pages like this
not linked directly; found by shared links- IdeaGive negative trials plenary slots at the big cancer conferences
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Failures are hidden, Knowledge reaches practice too slowly.
- IdeaMicro-learning pushed to community oncologists within 30 days of a practice change
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaFunded living systematic reviews for every major cancer indication
Shares Deposit trial results as structured data, not just PDFs, Knowledge reaches practice too slowly.
- IdeaLiving, machine-readable guidelines pushed to the point of care in every country
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaA guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaCap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO).
- IdeaOpen licences for publicly funded cancer guidelines
Shares European Society for Medical Oncology (ESMO), Knowledge reaches practice too slowly.
- IdeaOffline decision support for generalists treating common cancers in low-resource settings
Shares American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.